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OBJECTIVES: Finland has been amodel country for an organised
population-based cervical cancer (CC) screening programme.
Since its implementation in the 1960’s, both CC incidence and
mortality rates have reduced by 80% to annual 150 CC cases and
50–60 CC deaths. Our objective was to predict the clinical impact
of introducing prophylactic vaccination against human papillo-
mavirus (HPV) within a well functioning organised population-
based screening system and to evaluate the cost-effectiveness of
vaccination using a cohort based Markov model. METHODS:
The model is based upon lifetime Markov processes using
Microsoft Excel, modelling the natural history of HPV infection
and CC over the lifetime of a one age-cohort of girls. The model
simulates the effect of adding vaccination to the current screening
programme in terms of number of pre-cancerous lesions, CC cases
and CC deaths avoided. Data is collected from literature review,
expert opinion and statistics in Finland. All country speciﬁc data
were reviewed with national experts. Screening coverage was
assumed to remain constant over time in the model (2.1 million
eligible women and ca. 500,000 annual Pap smears divided into
different screening patterns). RESULTS: With 90% vaccination
coverage, coinciding with the coverage of the Finnish mass vacci-
nation programme, the model predicts a 66% reduction in CC
cases and in CC deaths (from 166 to 56 and from 56 to 19,
respectively). Cost-effectiveness was estimated assuming vaccine
price of €120/dose, including administration. With the assumed
coverage the undiscounted ICERwould be less than €7000/QALY.
CONCLUSION:AlthoughCC cases and deaths are relatively rare
in Finland, it would still be very cost-effective to implement
prophylactic cervical cancer vaccination. Additional beneﬁts
include avoidance of pre-cancerous lesions, the resource use
related to these and their adverse utility effects.
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OBJECTIVES: The efﬁciency of the Finnish cervical cancer (CC)
screening system is renowned. Consequently, the burden of CC in
Finland is amongst the lowest in the world. Our objective was to
validate, in this unusual setting, a cohort based Markov model
developed for estimating the clinical and health economic impact
of adding a prophylactic vaccine against cervical cancer to an
existing screening programme. METHODS: An existing Markov
model describing the natural history of high-risk HPV infections
to CC combined with screening was customized to the Finnish
setting. Basic calibration was performed using published data and
information on the existing screening programme. One third of
total annual pap smears are taken within organized population-
based screening. However, the remaining two thirds of total paps
(private spontaneous screening) are crucial for the outcomes. In
our model, spontaneous screening was extrapolated assuming a
similar age-speciﬁc distribution to organised screening. Themodel
outcomes of a cohort of 30,000 girls aged 11 years were validated
against the age-speciﬁc annual number of total pap smears, CC
incidence and CC mortality reported over the last 15 years in
Finnish statistics.RESULTS:Observed age-speciﬁc CC incidences
and deaths were closely replicated by the model (correlation
coefﬁcients 0.702 and 0.826, respectively). Overall predicted and
observedCC incidence andmortality adjusted forworld standard-
ized population per 100,000 women coincide (CC 4.2 vs. 4.0;
mortality 1.2 vs. 1.2, respectively). The predicted lifetime number
of pre-cancerous lesions for the cohort were 14,462 (CIN1) and
1,646 (CIN2-3). The model predicts that vaccination at 90%
coverage would reduce CC cases andmortality by 66% (166 to 56
cases; 56 to 19 deaths). CONCLUSION: A Markov model can be
used to replicate cancer incidence and mortality in the unique
Finnish setting. This model predicts health beneﬁts and cost-
effectiveness of a vaccine against cervical cancer in Finland.
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INCORPORATING PROBABILISTIC ATTRIBUTES IN A
STATED-CHOICE RISK-BENEFIT SURVEY
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OBJECTIVES: The objective of this study is to elicit preferences
for hypothetical risks and beneﬁts of antiretroviral (ART) treat-
ment among treatment-naïve HIV-positive African-Americans
using a stated-choice (SC) survey with probabilistic attribute
levels. SC surveys often include attributes that describe disease
outcomes and treatment features as discrete levels. Rarely do
studies describe attributes in probabilistic terms. Understanding
and conceptualizing numerical probabilities often is cognitively
challenging. Researchers have experimented with various graphi-
cal representations to assist respondents in understanding quan-
titative risks, but there is no general consensus about the most
effective approach. METHODS: In a recent study to estimate the
willingness of treatment-naïve HIV-positive African-Americans to
accept adverse event risks in exchange for improvements in treat-
ment efﬁcacy, four of the ﬁve attributes were described as prob-
abilities. We relied on a format that portrays absolute risks using
a risk grid in which each square of the grid represents one person.
Respondents completed an online survey instrument that included
a series of 10 SC tasks. Each hypothetical treatment alternative
included different probabilities of virologic failure, hypersensitiv-
ity reaction, bone damage, and kidney damage. The ﬁfth attribute
described discrete outcomes of bone or kidney damage (degree to
which the problem could be treated successfully). We included
four questions that tested their understanding of the risk grid
format prior to completing the choice questions. RESULTS: In
total, 153 respondents completed the survey. The mean (SD) age
was 42 (8.6) and there were slightly more males (58%) than
females (42%). Seventy-four percent (89%) of respondents
answered the ﬁrst (fourth) risk quiz question correctly indicating
a high level of comprehension of risk levels.CONCLUSION:Our
risk grid approach, which included both a numerical and graphi-
cal representation of absolute risk levels, is an appropriatemethod
for including probabilistic attribute levels in SC surveys.
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OBJECTIVES: Due to changes in population, health care system
and methodological factors the external validity of economic
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evaluations is typically not long lasting. We investigated the
major factors affecting the “expiration date” of economic evalu-
ations using conjugate meningococcal vaccination strategies as
case example. METHODS: In March 2007, we conducted a
systematic literature review of journal articles, based on a
comprehensive key-word based search in generic (PUBMED,
EMBASE) and specialized electronic databases (HEED, NHS
EED), accompanied by manual searches of speciﬁc journals. The
applied methodology in the identiﬁed studies was compared
and matched to the respective national guidelines for economic
evaluation. The current external validity of the study results
and possible adjustments for its improvement were examined.
RESULTS: A total of six published economic evaluations of
conjugate meningococcal vaccination strategies were found.
Overall, they showed that the investigated vaccination strategies
were cost-effective, especially the ones targeting children at
approximately age 1. Adherence of the evaluations to the respec-
tive guidelines was high except for the discount rate. The latter
was however directly related to the recent change in Dutch and
UK recommendations. Sensitivity analysis was available for
many factors, inclusive the discount rate allowing the estimation
of the impact of those recent changes. Similarly, the effect of new
ﬁndings about the vaccination protection duration and herd
immunity could also be estimated for those evaluations that
included those factors in their sensitivity analysis. These were
however scarce. CONCLUSION: An extensive sensitivity analy-
sis for all important factors that might change over time can
extend the expiration date of economic evaluations. Ultimately,
user-friendly and highly ﬂexible models available on the internet
might be the best way to transfer study results over time.
INFECTION—Patient Reported Outcomes
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OBJECTIVES: The purpose of this study was to validate cross-
sectionally the MINI-HIV questionnaire in HIV patients treated
with saquinavir in Spanish hospitals. METHODS: Cross-
sectional observational post-launch and multicentre study. HIV
Patients over 18 years, who were under HAART with Saquinavir.
One visit was carried out. Socio-demographic and clinical vari-
ables (symptoms, time since HIV diagnosis, CDC stage, CD4 and
viral load), treatment adherence (GEEMA questionnaire), a ques-
tion about general health status and the speciﬁc QoL question-
naire Mini-HIV (0 = better QoL; 100 = worse Qol) were
collected. RESULTS: A total of 948 patients were included.
Mean age (SD) was 42 (8.62) years. Mean (SD) time since diag-
nosis was 11.3 (5.6). A total of 36.1% were in Stage C of CDC.
Mean score (SD) obtained in Mini-HIV was of 30.2 (17.8). A
total of 64.9% had bad Qol (cut of point under 22 score).
Correlation between Mini-HIV score and CD4 was low (-0.134)
although it was signiﬁcant (p < 0.01). In patients with detectable
viral load mean (SD) of MINI-HIV score was lower than in
patients with undetectable viral load (32.9 (18.1) vs. 28.8 (17.5);
p < 0.01). QoL was worse in patients who presented symptoms
in the last two weeks or that presented other concomitant disease
(p < 0.01). The more frequent symptoms were weakness, anxiety,
insomnia and depression. There was no difference in MINI-HIV
score according to the form of administration (BID vs OD).
Internal consistency of MINI-HIV was of 0.914 (higher than 0.7
theoretical). General health status was ‘very good’ in 42.3% of
the patients. MINI-HIV scores were related to the general health
status question (p < 0.01). Non adherent patients obtained
higher scores (worse Qol) than adherent patients (p < 0.01).
CONCLUSION: The results of this study show that Mini-HIV
has good psychometrical properties and can be a good tool for
monitoring treatment effectiveness and health states of HIV
patients.
PIN47
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OBJECTIVES: To develop and validate a self-administered ques-
tionnaire assessing subjects’ perception and experience with
injection, and their acceptance of injection site reactions (ISR)
including pain following inﬂuenza vaccination. METHODS: Fol-
lowing a literature review, the VAPI questionnaire was simulta-
neously developed in US English, German and French, based on
interviews of subjects (n = 33) vaccinated intramuscularly (IM)
or intradermally (ID) with an inﬂuenza vaccine. Items were
generated from subjects’ verbatim, comprehension tested with
elderly and adult vaccinees (n = 23); then a linguistic validation
was done. The initial, 44 item-version of the questionnaire was
administered 21 days after vaccination to subjects from Belgium,
France, Spain, the UK, Germany and Italy who were participat-
ing in clinical trials comparing ID versus IM inﬂuenza vaccina-
tion.Scale construction and item reduction were conducted using
principal component and multitrait analyses with 549 English
subjects. Psychometric validation of the ﬁnal questionnaire was
performed per country (n = 5,543) and included: 1) construct
validity by item convergent and discriminant validity, 2) internal
consistency reliability by Cronbach’s alpha and 3) clinical valid-
ity by describing the scores according to ISR severity. RESULTS:
After item reduction, the ﬁnal questionnaire comprised 4 multi-
item dimensions (“bother”; “arm movement”; “sleep”; “accept-
ability”) grouping 16 items plus 5 individual items (anxiety
before vaccination; bother by pain during vaccination; satisfac-
tion with the injection system; anxiety of being vaccinated next
year; willingness to be vaccinated again). Item convergent and
discriminant validity was conﬁrmed for all scales in most coun-
tries. Multi-item dimension internal consistency reliability was
good to excellent for all countries (Cronbach’s alpha ranging
from 0.73 to 0.94), except for the “sleep” dimension in Italy
(0.68). Dimension scores demonstrated good clinical validity:
greater severity of ISR was associated with higher scores. CON-
CLUSION: The self-administered VAPI questionnaire is valid
and reliable. Therefore, it is a promising tool for the assessment
of the acceptance of a vaccine injection system.
METHODS & CONCEPTS
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OBJECTIVES: Compare data from a large national EMR in the
US to national published data. METHODS: Data from GE
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